Advertisement
Research Article
Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway
Samah W. Awwad, Nabieh Ayoub
Biology Open 2015 4: 498-504; doi: 10.1242/bio.201410991

Abstract

The KDM4 family of lysine demethylases consists of five members, KDM4A, -B and -C that demethylate H3K9me2/3 and H3K36me2/3 marks, while KDM4D and -E demethylate only H3K9me2/3. Recent studies implicated KDM4 proteins in regulating genomic instability and carcinogenesis. Here, we describe a previously unrecognized pathway by which hyperactivity of KDM4 demethylases promotes genomic instability. We show that overexpression of KDM4A-C, but not KDM4D, disrupts MSH6 foci formation during S phase by demethylating its binding site, H3K36me3. Consequently, we demonstrate that cells overexpressing KDM4 members are defective in DNA mismatch repair (MMR), as evident by the instability of four microsatellite markers and the remarkable increase in the spontaneous mutations frequency at the HPRT locus. Furthermore, we show that the defective MMR in cells overexpressing KDM4C is mainly due to the increase in its demethylase activity and can be mended by KDM4C downregulation. Altogether, our data suggest that cells overexpressing KDM4A-C are defective in DNA MMR and this may contribute to genomic instability and tumorigenesis.

INTRODUCTION

A decade ago, two families of lysine demethylases (KDM) have been identified, confirming that lysine methylation is a reversible and dynamically regulated process (Klose et al., 2006a; Shi et al., 2004; Whetstine et al., 2006). One family is referred to as the Jumonji C (JmjC)-domain-containing proteins. The crystal structure of the JmjC catalytic domain was solved and found to form an enzymatically active pocket that coordinates the two main co-factors needed for the radical-based oxidative demethylation reaction, ferrous oxide (Fe(II)) and α-ketoglutarate (Chen et al., 2006; Shi and Whetstine, 2007; Tsukada et al., 2006).

The human KDM4A-E family (also known as JMJD2A-E) consists of five members, which specifically catalyze the demethylation of H3K9me2/me3. Furthermore, KDM4A, -B and -C, but not KDM4D and -E, demethylate H3K36me2/me3 and H1.4K26me2/me3 (Chen et al., 2006; Labbé et al., 2013; Trojer et al., 2009). KDM4A-E proteins are involved in multiple cellular processes including gene expression regulation (Kim et al., 2012; Mallette and Richard, 2012; Shin and Janknecht, 2007a; Wissmann et al., 2007; Zhang et al., 2005), DNA replication (Black et al., 2010; Black et al., 2012), and DNA damage response (Khoury-Haddad et al., 2014; Mallette et al., 2012; Palomera-Sanchez et al., 2010; Young et al., 2013; Black, 2012), worm development and germ cell apoptosis (Whetstine et al., 2006), renewal of embryonic stem cells (Loh et al., 2007), and male life span in drosophila (Lorbeck et al., 2010). Interestingly, increasing number of reports implicate KDM4 misregulation in promoting genomic instabilities and carcinogenesis (Berdel et al., 2012; Berry and Janknecht, 2013; Black et al., 2013; Cloos et al., 2006; Ehrbrecht et al., 2006; Italiano et al., 2006; Kawazu et al., 2011; Labbé et al., 2013; Li et al., 2011; Liu et al., 2009; Luo et al., 2012; Northcott et al., 2009; Shi et al., 2011; Vinatzer et al., 2008; Wissmann et al., 2007; Yang et al., 2000; Zack et al., 2013).

A recent report implicated H3K36me3 mark in DNA mismatch repair (MMR). It demonstrated that the mismatch recognition protein hMutSα binds H3K36me3 during early S phase to ensure intact DNA MMR (Li et al., 2013). These observations prompted us to investigate the role of KDM4 proteins in DNA MMR. Here, we describe a previously unrecognized pathway by which upregulation of KDM4 proteins promotes genomic instability. We show that overexpression of KDM4 impairs the integrity of DNA mismatch repair (MMR) and thus leading to microsatellite instability (MSI) and to an increase in the frequency of spontaneous mutations. Interestingly, we show that downregulation of KDM4C expression restores the integrity of DNA MMR. Collectively, our data provide a new pathway by which KDM4A-C amplification may lead to genomic instability and tumorigenesis.

RESULTS AND DISCUSSION

KDM4A-C overexpression disrupts MSH6 foci formation during S-phase

KDM4A-C proteins, but not KDM4D, demethylate H3K36me3 mark as we and others have shown (Couture et al., 2007; Hillringhaus et al., 2011; Klose et al., 2006b; Kupershmit et al., 2014; Shin and Janknecht, 2007b; Whetstine et al., 2006). H3K36me3 is involved in DNA MMR as it provides a binding site for the MMR protein MSH6 and enables MSH6 foci formation during S phase (Li et al., 2013). Therefore, we sought to assess whether overexpression of KDM4A-C proteins affects MSH6 foci during S phase. Toward this end, we used U2OS-TetON cell lines that conditionally express functional EGFP-KDM4A-C fusions upon the addition of doxycycline (Ipenberg et al., 2013; Kupershmit et al., 2014). Importantly, the expression levels of EGFP-KDM4A-C fusions are comparable to the levels of the endogenous KDM4A-C proteins found in human breast adenocarcinoma cell line, MCF7, known to have elevated levels of KDM4 proteins (Berry and Janknecht, 2013; Berry et al., 2012) (Fig. 1A). The cells were synchronized at G1/S border using double-thymidine block; samples were collected at 3 hr after the removal of thymidine and subjected to both fluorescence-activated cell sorter (FACS) and immunofluorescence (IF). Results show that 3 hr after thymidine removal the majority of the cells (83%) were at S phase (supplementary material Fig. S1). IF analysis shows that overexpression of EGFP-KDM4A-C fusions (green) diminished the intensity of H3K36me3 signal (gray) and impaired MSH6 foci during S phase (red) (Fig. 1B–D). On the other hand, U2OS-TetON cells expressing EGFP-KDM4D fusion (Khoury-Haddad et al., 2014), which does not demethylate H3K36me3, show no detectable effect on H3K36me3 levels and MSH6 foci (Fig. 1E). Quantitative measurements of the MSH6 foci reveal that KDM4A-C overexpression leads to 6–9 fold decrease comparing to control U2OS cell line or cells overexpressing KDM4D (Fig. 1F). We concluded therefore that EGFP-KDM4A-C overexpression leads to a dramatic reduction in H3K36me3 and impairs MSH6 foci during the S phase of the cell cycle. Our results are consistent with a recent report showing that MSH6 foci during S phase is impaired following the inhibition of H3K36me3 methylation by knocking down SETD2 methyltransferase (Li et al., 2013).

Fig. 1.
Fig. 1. Overexpression of KDM4A-C, but not KDM4D, proteins impairs MSH6 foci formation during S-phase.

(A) Western blot analysis shows the levels of EGFP-KDM4A-C fusions in U2OS-TetON cell lines in comparison to the levels of the endogenous KDM4A-C proteins in MCF7 cell line. Protein extracts were prepared from MCF7 cell line and from doxycycline-treated U2OS-TetON cells expressing EGFP-KDM4A-C fusions and immunoblotted using the indicated antibodies. β-actin is used as a loading control. EGFP-KDM4A-C fusions and the endogenous KDM4A-C proteins are indicated by arrowheads and stars, respectively. (B–E) Shows that overexpression of EGFP-KDM4A-C, but not EGFP-KDM4D, catalyzes the removal of H3K36me3 methylation and impairs MSH6 foci formation during S phase. Cells were fixed and subjected to immunofluorescence analysis using antibodies against MSH6 (red) and H3k36me3 (gray). DNA is stained with DAPI (blue) and EGFP-KDM4A-D fusions are in green. Results shown in (B–E) are typical of two independent experiments and represent at least 30 different cells each. (F) Graph shows the number of MSH6 foci in untransfected U2OS cells and in U2OS cells expressing EGFP-KDM4A-D fusions (n = 30 cells). Foci were counted by eye. Error bars represent SD from two independent experiments. Scale bars = 10 µm (B,C,E); 5 µm (D).

Overexpression of KDM4 members impairs the integrity of DNA mismatch repair

It was shown that H3K36me3-MSH6 interaction is essential for intact DNA MMR (Li et al., 2013). We predicted therefore that the removal of H3K36me3 mark following KDM4A-C overexpression should disrupt the integrity of DNA MMR. Given that microsatellite instability (MSI) is a common hallmark of MMR-defective cells (Boland et al., 1998; Bocker et al., 1997; Ellegren, 2004; Hsieh and Yamane, 2008), we sought to test the stability of the mononucleotide (BAT25, BAT26) and the dinucleotide (D2S123, D5S346) microsatellite markers in U2OS-TetON cell lines overexpressing EGFP-KDM4A-D proteins. MSI assay was performed on genomic DNA, which was extracted from 20 clones derived from different single cells of each cell line. Results show that cells overexpressing KDM4A-C, but not KDM4D, exhibit MSI as evidence by the appearance of new repeat species (marked by *) and complete deletions of the tested markers (marked by Δ). As shown in Fig. 2A, 40% (8/20 clones), 55% (11/20) and 30% (6/20) of the clones expressing KDM4A, B and C respectively, show either deletion or novel microsatellite mark. On the other hand, no detectable alterations in the length of the four tested microsatellite markers were obtained in clones overexpressing KDM4D (Fig. 2D) and only one clone shows deletion in the control U2OS-TetON cells (Fig. 2E).

Fig. 2.
Fig. 2. Overexpression of KDM4A-C, but not KDM4D, displays MSI phenotype.

(A–E) Microsatellite instability (MSI) assay showing the analysis of PCR product patterns of four microsatellite markers in subclones derived from U2OS-TetON expressing EGFP fused to KDM4A (A), KDM4B (B), KDM4C (C), KDM4D (D) and U2OS-TetON control cells (E). To determine the microsatellite stability, genomic DNA was extracted from 20 single clones derived from different single cells of each cell line. The indicated microsatellite markers were then amplified using specific primers pairs, resolved by polyacrylamide-urea electrophoresis and visualized by SYBR-Gold staining. Δ and * show clones exhibiting complete deletion of the tested microsatellite markers or new repeat species, respectively.

Clones with two or more abnormal microsatellite marker are scored as MSI-high (MSI-H), while MSI-low clones have only one unstable marker (Boland et al., 1998; Haydon and Jass, 2002; Merok et al., 2013). Based on this classification, we observed that U2OS-TetON-EGFP-KDM4A cells contain two MSI-H clones, clone #7 (shows instability in 2 out of 4 markers) and clone#17 (shows instability in 3 out of 4 markers) (Fig. 2A). Further, U2OS-TetON-EGFP-KDM4B cells contain 4 MSI-H clones, clone #2, clone#13, clone#15 and clone#18 (each shows instability in 2 out of 4 markers) (Fig. 2B). Further, clone#20 of U2OS-TetON-EGFP-KDM4C cells shows instability in all four tested markers (Fig. 2C). On the other hand, no MSI-H clones were observed in U2OS-TetON-EGFP-KDM4D (Fig. 2D) and in U2OS-TetON control cells (Fig. 2E).

Notably, the sizes of the observed new microsatellite alleles are similar (Fig. 2). This could be due to continuous overexpression of KDM4A-C protein for prolong time (2–3 weeks) which leads to selective growth advantage of clones with a certain length of microsatellite markers. To address this possibility, we repeated the MSI assay on cells that overexpressed EGFP-KDM4C for four days only. Results show that 85% of the clones are MSI-H. Interestingly, unlike the situation in Fig. 2C, we observed novel alleles with heterogeneous repeat length, suggesting that indeed prolong expression of KDM4C may lead to the appearance of novel alleles with uniform size (supplementary material Fig. S2). Altogether, our data suggest that overexpression of KDM4A-C, but not KDM4D, disrupts the integrity of DNA MMR and leads to MSI.

A second readout of a defective DNA MMR is the increase in the spontaneous mutation frequency (Albertini, 2001; Branch et al., 1995; Eshleman et al., 1995). Therefore we performed HPRT mutability assay to determine the mutation frequency at the HPRT locus in cells overexpressing KDM4A-D members (see Materials and Methods; supplementary material Fig. S3). Results show that KDM4A-C overexpression leads to a dramatic increase in the mutation frequency which is between ∼500–1000 folds comparing to the control U2OS-TetON cells (Table 1). Surprisingly, cells overexpressing KDM4D show also significant increase in the mutation frequency (32.5 fold increase), however it is at least 15 fold less than the increase observed in cells overexpressing KDM4A-C fusions (Table 1). Altogether, we concluded that overexpression of KDM4A-C proteins leads to a remarkable increase in the mutation frequency, highlighting the key role of H3K36me3 in regulating the DNA MMR pathway. In addition, the increased mutation frequency in cells overexpressing KDM4D suggests that methylation marks other than H3K36me3 might be also implicated in regulating the fidelity of DNA MMR. Interestingly, the proteins levels of the four key MMR genes MSH6, MSH2, MLH1 and PMS2 are not reduced in cells overexpressing KDM4 proteins (supplementary material Fig. S4), suggesting that the defective DNA MMR is not due to decrease in the levels of the tested key MMR proteins. Notably, overexpression of KDM4A-D proteins leads to 1.9 and 1.5 fold increase in the protein levels of MLH1 and MSH6, respectively.

View this table:
Table 1. KDM4A-D overexpression increases the mutation frequency at the HPRT locus

Overactivity of KDM4C demethylase disrupts the integrity of DNA MMR

We show that the decrease in H3K36me3 levels following KDM4A-C overexpression impairs MSH6 foci formation and disrupts the integrity of DNA MMR (Figs 1, 2 and Table 1). These findings suggest that the levels of H3K36me3 have a critical role in regulating DNA MMR pathway. To further validate this, we monitored the integrity of MMR in cells overexpressing KDM4C demethylase-dead mutant. Previously, we have established a catalytically inert KDM4C-S198M mutant that does not demethylate H3K9me3 (Kupershmit et al., 2014). Here, we validated by western blot that KDM4C-S198M overexpression also has no effect on the levels of H3K36me3 (Fig. 3A). To assess the integrity of MMR, cells overexpressing KDM4C-S198M were subjected to MSI and HPRT mutability assays. The MSI results show no MSI-H clones and only one out of the 20 tested clones overexpressing KDM4C-S198M shows complete deletion of BAT25 marker (Fig. 3B). In addition, the HPRT mutability assay shows that the mutation frequency in cells overexpressing KDM4C-S198M is ∼7 fold less than in cells overexpressing KDM4C-WT (Table 1). Nonetheless, KDM4C-S198M overexpression shows significant increase in the mutation frequency (∼75 fold) at the HPRT locus comparing to U2OS-TetON cells. Altogether, our findings confirm that the defective DNA MMR in cells overexpressing KDM4 results mainly from the increase in the demethylase activity. However, overexpression of the catalytically inert mutant has also a relatively minor effect on the integrity of DNA MMR. This result suggests that one mechanism by which KDM4C-S198M interferes with MMR might be by competing with MSH6 on binding to H3K36me3.

Fig. 3.
Fig. 3. KDM4C over-activity disrupts DNA MMR.

(A) Western blot analysis showing that overexpression of EGFP-KDM4C-S198M has no detectable effect on the levels of H3K36me3. Protein extracts were prepared from U2OS-TetON cells expressing either EGFP-KDM4C-WT or EGFP-KDM4C-S198M and immunoblotted using the indicated antibodies. (B) MSI assay was performed as described in Fig. 2 except that genomic DNA was extracted from 20 single clones derived from U2OS-TetON cells expressing KDM4C-S198M. Results show that only one clone out of 20 clones shows instability in a single marker. Δ shows clones exhibiting complete deletion of the tested microsatellite markers.

The KDM4C-dependent MMR defect is mended by KDM4C downregulation

Here, we asked whether the defective MMR in cell overexpressing KDM4C could be repaired by KDM4C downregulation. To address this question, we treated cells with doxycycline for five days to trigger EGFP-KDM4C overexpression and disrupt DNA MMR. Next, EGFP-KDM4C expression was shutdown by doxycycline removal and cells were subjected to HPRT mutability assay (Fig. 4A). To validate the shutting down of EGFP-KDM4C expression, we performed western blot before and after doxycycline removal (Fig. 4B). The HPRT mutability showed that the removal of doxycycline leads to a decrease of ∼26 fold in the mutation frequency comparing to cells overexpressing KDM4C protein (Table 1). This result strongly suggests that KDM4C downregulation restores the integrity of DNA MMR. Given that Microsatellite-stable (MSS) and MSI tumors display distinct responses to certain antitumor agents (Merok et al., 2013; Ribic et al., 2003; Vilar et al., 2008; Vilar and Tabernero, 2013), we speculate that small molecule inhibitors of KDM4C may restore the integrity of DNA MMR and alter the sensitivity to anticancer drugs.

Fig. 4.
Fig. 4. Downregulation of KDM4C restores the integrity of DNA mismatch repair.

(A) An outline describing the experimental flow to assess the effect of KDM4C downregulation on the rate of mutation frequency at the HPRT gene. Cells were cultured with doxycycline for 7 days to induce EGFP-KDM4C expression, then the doxycycline was removed to shutdown the expression of EGFP-KDM4C and subsequently the mutation frequency at the HPRT gene was determined. (B) Western blot showing that doxycycline removal suppresses the expression of EGFP-KDM4C fusion. Protein lysates from untreated and doxycycline-treated U2OS-TetON-EGFP-KDM4C cells were immunoblotted using the indicated antibodies. (C) A model showing that KDM4A-C overexpression diminishes H3K36me3 signal, impairs MSH6 foci and impairs the integrity of DNA MMR pathway.

Here we reveal a previously unrecognized role of KDM4A-C upregulation in modulating the fidelity of DNA MMR pathway. The model that emerges from our results suggests that defective MMR in cells overexpressing KDM4A-C is primarily due to the elevation of their demethylase activity, which is accompanied by a dramatic decrease in the levels of H3K36me3 and loss of MSH6 foci formation during S phase (Fig. 4C). Our observations are consistent with previous report showing that depletion of SETD2 methyltransferase reduces H3K36me3 levels, impairs MSH6 foci formation and disrupts DNA MMR (Li et al., 2013).

Interestingly, while KDM4D overexpression has no detectable effect on the stability of the four tested microsatellite markers (Fig. 2D), it leads to 32.5 fold increase in the mutation frequency at the HPRT locus (Table 1). This increase is independent of H3K36me3-MSH6 interactions because H3K36me3 levels are not affected by KDM4D overexpression (Fig. 1E). The KDM4D-dependent increase in the mutation frequency might be related to: (i) changes in the methylation marks of either histone other than H3K36me3 and/or non-histone proteins. Indeed, it was recently shown that KDM4D demethylates H3K56me3 (Jack et al., 2013) and non-histone substrates (Ponnaluri et al., 2009; Yang et al., 2011). (ii) Changes in the expression patterns of KDM4D target genes that might be implicated in the DNA MMR pathway. Future studies will be required to further clarify this issue.

MATERIALS AND METHODS

Cell lines and growth conditions

All cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) as previously described (Ipenberg et al., 2013; Khoury-Haddad et al., 2014; Kupershmit et al., 2014).

Cell synchronization

U2OS-TetON-EGFP-KDM4A-D cells were synchronized at G1/S by double thymidine block as previously described (Lee et al., 2004).

Flow cytometry

FACS analysis was performed as previously described (Khoury-Haddad et al., 2014). DNA content was analyzed using flow cytometry of 10,000 events on a BD LSR-II flow cytometer (Becton Dickinson), equipped with FCS Express software. Data were analyzed using ModFit LT 3.3 software.

Western blotting

Western blotting was performed as previously described (Khoury-Haddad et al., 2014). Briefly, protein lysates were prepared using hot-lysis and immunoblotted using the appropriate antibodies (a complete list of antibodies and their dilutions used in this study are described in supplementary material Table S1). Membranes were developed using Quantum ECL detection kit (K-12042-D20, Advansta).

Immunofluorescence

Cells were grown on coverslips and subjected to immunofluorescence as previously described (Khoury-Haddad et al., 2014). Cells were stained with the appropriate antibodies (supplementary material Table S1). Slides were visualized using the inverted Zeiss LSM 700 confocal microscope with 40× oil EC Plan Neofluar objective.

Microsatellite instability assay (MSI)

U2OS-TetON control cell line and U2OS-TetON cell lines expressing EGFP-KDM4A-D and EGFP-KDM4C-S198M fusions were plated at limiting dilutions for an average density of 100–500 cells into 15 cm plates. By 2–3 weeks after plating, genomic DNA was extracted from 20 single clones of each cell line using the NucleoSpin Tissue XS kit. MSI assay was performed as previously described (Bocker et al., 1997; Boland et al., 1998). In brief, four microsatellite markers (BAT25, BAT26, D2S123 and D5S346) were amplified using PCR, the amplified PCR products were resolved by electrophoresis in an 8% polyacrylamide gel containing 7.7 M urea, stained with SYBR Gold (Life Technologies 1308457) and visualized using the Gel Doc™ XR+ imaging system.

HPRT mutability assay

The HPRT mutability assay was performed as described in (Glaab et al., 1998; Glaab and Tindall, 1997; Kat et al., 1993), except for the following changes. Cells were cultured in growth medium containing 100 µM hypoxanthine, 0.4 µM aminopterin and 16 µM Thymidine (HAT) for 5 days to eliminate the pre-existing HPRT mutant cells. Next, the cells were transferred to HAT-free medium and treated with doxycycline for 3 days to trigger the expression of the EGFP-KDM4 fusions. Afterward, 9×106 cells were plated in medium containing 5 µM 6-Thioguanine (6-TG; Sigma#A4660) and 1 µg/ml doxycycline at a density of 3×106 per 10 cm dish. In addition, 1.5×103 cells were plated at a density of 500 cells per 6 cm dish containing doxycycline but without 6-TG to determine plating efficiency. The plates were incubated at 37°C in humidified incubator for 21–30 days. The colonies were visualized by staining with 0.005% crystal violet and colonies containing more than ∼50 individual cells are counted using a stereomicroscope. The mutation frequency (MF) was calculated according to the following equation: MF = a/(9×106×[b/1.5×103]). a = total number of 6-TG resistant colonies and b = total number of colonies observed in the plating efficiency plates.

Acknowledgements

We thank Hanan Khoury-Haddad for her critical reading of the manuscript, Yehuda Assaraf for his support and critical advice. We thank Maayan Duvshani-Eshet, Nitzan Dahan and Efrat Barak, from the Life Sciences and Engineering Infrastructure Unit at the Technion, for their help in the microscopy and flow-cytometry-related works. We are grateful for Rotem Karni for the generous gift of MSH2 antibody.

Funding

This study is supported by grants from the Israel Science Foundation [2014673]; the Israel Cancer association [2019404]; the H. Blechman Memorial Cancer Research Fund; and Eliayahu Pen Research Fund [2018025].

Footnotes

  • Author Contributions S.W.A. planed and performed all the experiments described in this study, wrote the materials and methods and helped in proofreading the manuscript. N.A. conceived the study, planed the experiments and wrote the paper.

  • Competing interests The authors declare no competing or financial interests.

  • Received November 19, 2014.
  • Accepted January 20, 2015.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    1. Albertini R. J.
    (2001). HPRT mutations in humans: biomarkers for mechanistic studies. Mutat. Res. 489, 1–16. doi:10.1016/S1383-5742(01)00064-3
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Berdel B.,
    2. Nieminen K.,
    3. Soini Y.,
    4. Tengström M.,
    5. Malinen M.,
    6. Kosma V. M.,
    7. Palvimo J. J.,
    8. Mannermaa A.
    (2012). Histone demethylase GASC1 – a potential prognostic and predictive marker in invasive breast cancer. BMC Cancer 12, 516. doi:10.1186/1471-2407-12-516
    OpenUrlCrossRefPubMed
  3. ↵
    1. Berry W. L.,
    2. Janknecht R.
    (2013). KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 73, 2936–2942. doi:10.1158/0008-5472.CAN-12-4300
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Berry W. L.,
    2. Shin S.,
    3. Lightfoot S. A.,
    4. Janknecht R.
    (2012). Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int. J. Oncol. 41, 1701–1706. doi:10.3892/ijo.2012.1618
    OpenUrlCrossRefPubMed
  5. ↵
    1. Black J. C.,
    2. Allen A.,
    3. Van Rechem C.,
    4. Forbes E.,
    5. Longworth M.,
    6. Tschöp K.,
    7. Rinehart C.,
    8. Quiton J.,
    9. Walsh R.,
    10. Smallwood A.
    et al. (2010). Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Mol. Cell 40, 736–748. doi:10.1016/j.molcel.2010.11.008
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Black J. C.,
    2. Van Rechem C.,
    3. Whetstine J. R.
    (2012). Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 48, 491–507. doi:10.1016/j.molcel.2012.11.006
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Black J. C.,
    2. Manning A. L.,
    3. Van Rechem C.,
    4. Kim J.,
    5. Ladd B.,
    6. Cho J.,
    7. Pineda C. M.,
    8. Murphy N.,
    9. Daniels D. L.,
    10. Montagna C.
    et al. (2013). KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 154, 541–555. doi:10.1016/j.cell.2013.06.051
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Bocker T.,
    2. Diermann J.,
    3. Friedl W.,
    4. Gebert J.,
    5. Holinski-Feder E.,
    6. Karner-Hanusch J.,
    7. von Knebel-Doeberitz M.,
    8. Koelble K.,
    9. Moeslein G.,
    10. Schackert H. K.
    et al. (1997). Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. 57, 4739–4743.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Boland C. R.,
    2. Thibodeau S. N.,
    3. Hamilton S. R.,
    4. Sidransky D.,
    5. Eshleman J. R.,
    6. Burt R. W.,
    7. Meltzer S. J.,
    8. Rodriguez-Bigas M. A.,
    9. Fodde R.,
    10. Ranzani G. N.
    et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248–5257.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Branch P.,
    2. Hampson R.,
    3. Karran P.
    (1995). DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res. 55, 2304–2309.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Chen Z.,
    2. Zang J.,
    3. Whetstine J.,
    4. Hong X.,
    5. Davrazou F.,
    6. Kutateladze T. G.,
    7. Simpson M.,
    8. Mao Q.,
    9. Pan C. H.,
    10. Dai S.
    et al. (2006). Structural insights into histone demethylation by JMJD2 family members. Cell 125, 691–702.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Cloos P. A.,
    2. Christensen J.,
    3. Agger K.,
    4. Maiolica A.,
    5. Rappsilber J.,
    6. Antal T.,
    7. Hansen K. H.,
    8. Helin K.
    (2006). The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442, 307–311. doi:10.1038/nature04837
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Couture J. F.,
    2. Collazo E.,
    3. Ortiz-Tello P. A.,
    4. Brunzelle J. S.,
    5. Trievel R. C.
    (2007). Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat. Struct. Mol. Biol. 14, 689–695. doi:10.1038/nsmb1273
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Ehrbrecht A.,
    2. Müller U.,
    3. Wolter M.,
    4. Hoischen A.,
    5. Koch A.,
    6. Radlwimmer B.,
    7. Actor B.,
    8. Mincheva A.,
    9. Pietsch T.,
    10. Lichter P.
    et al. (2006). Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 208, 554–563. doi:10.1002/path.1925
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Ellegren H.
    (2004). Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet. 5, 435–445. doi:10.1038/nrg1348
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Eshleman J. R.,
    2. Lang E. Z.,
    3. Bowerfind G. K.,
    4. Parsons R.,
    5. Vogelstein B.,
    6. Willson J. K.,
    7. Veigl M. L.,
    8. Sedwick W. D.,
    9. Markowitz S. D.
    (1995). Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10, 33–37.
    OpenUrlPubMedWeb of Science
  17. ↵
    1. Glaab W. E.,
    2. Tindall K. R.
    (1997). Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 18, 1–8. doi:10.1093/carcin/18.1.1
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Glaab W. E.,
    2. Risinger J. I.,
    3. Umar A.,
    4. Barrett J. C.,
    5. Kunkel T. A.,
    6. Tindall K. R.
    (1998). Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis 19, 1931–1937. doi:10.1093/carcin/19.11.1931
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Haydon A. M.,
    2. Jass J. R.
    (2002). Emerging pathways in colorectal-cancer development. Lancet Oncol. 3, 83–88. doi:10.1016/S1470-2045(02)00649-6
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Hillringhaus L.,
    2. Yue W. W.,
    3. Rose N. R.,
    4. Ng S. S.,
    5. Gileadi C.,
    6. Loenarz C.,
    7. Bello S. H.,
    8. Bray J. E.,
    9. Schofield C. J.,
    10. Oppermann U.
    (2011). Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. J. Biol. Chem. 286, 41616–41625. doi:10.1074/jbc.M111.283689
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Hsieh P.,
    2. Yamane K.
    (2008). DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 129, 391–407. doi:10.1016/j.mad.2008.02.012
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Ipenberg I.,
    2. Guttmann-Raviv N.,
    3. Khoury H. P.,
    4. Kupershmit I.,
    5. Ayoub N.
    (2013). Heat shock protein 90 (Hsp90) selectively regulates the stability of KDM4B/JMJD2B histone demethylase. J. Biol. Chem. 288, 14681–14687. doi:10.1074/jbc.C113.462770
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Italiano A.,
    2. Attias R.,
    3. Aurias A.,
    4. Pérot G.,
    5. Burel-Vandenbos F.,
    6. Otto J.,
    7. Venissac N.,
    8. Pedeutour F.
    (2006). Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet. Cytogenet. 167, 122–130. doi:10.1016/j.cancergencyto.2006.01.004
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Jack A. P.,
    2. Bussemer S.,
    3. Hahn M.,
    4. Pünzeler S.,
    5. Snyder M.,
    6. Wells M.,
    7. Csankovszki G.,
    8. Solovei I.,
    9. Schotta G.,
    10. Hake S. B.
    (2013). H3K56me3 is a novel, conserved heterochromatic mark that largely but not completely overlaps with H3K9me3 in both regulation and localization. PLoS ONE 8, e51765. doi:10.1371/journal.pone.0051765
    OpenUrlCrossRefPubMed
  25. ↵
    1. Kat A.,
    2. Thilly W. G.,
    3. Fang W. H.,
    4. Longley M. J.,
    5. Li G. M.,
    6. Modrich P.
    (1993). An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA 90, 6424–6428. doi:10.1073/pnas.90.14.6424
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kawazu M.,
    2. Saso K.,
    3. Tong K. I.,
    4. McQuire T.,
    5. Goto K.,
    6. Son D. O.,
    7. Wakeham A.,
    8. Miyagishi M.,
    9. Mak T. W.,
    10. Okada H.
    (2011). Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS ONE 6, e17830. doi:10.1371/journal.pone.0017830
    OpenUrlCrossRefPubMed
  27. ↵
    1. Khoury-Haddad H.,
    2. Guttmann-Raviv N.,
    3. Ipenberg I.,
    4. Huggins D.,
    5. Jeyasekharan A. D.,
    6. Ayoub N.
    (2014). PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair. Proc. Natl. Acad. Sci. USA 111, E728–E737. doi:10.1073/pnas.1317585111
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Kim T. D.,
    2. Oh S.,
    3. Shin S.,
    4. Janknecht R.
    (2012). Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS ONE 7, e34618. doi:10.1371/journal.pone.0034618
    OpenUrlCrossRefPubMed
  29. ↵
    1. Klose R. J.,
    2. Kallin E. M.,
    3. Zhang Y.
    (2006a). JmjC-domain-containing proteins and histone demethylation. Nat. Rev. Genet. 7, 715–727. doi:10.1038/nrg1945
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Klose R. J.,
    2. Yamane K.,
    3. Bae Y.,
    4. Zhang D.,
    5. Erdjument-Bromage H.,
    6. Tempst P.,
    7. Wong J.,
    8. Zhang Y.
    (2006b). The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442, 312–316. doi:10.1038/nature04853
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Kupershmit I.,
    2. Khoury-Haddad H.,
    3. Awwad S. W.,
    4. Guttmann-Raviv N.,
    5. Ayoub N.
    (2014). KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis. Nucleic Acids Res. 42, 6168–6182. doi:10.1093/nar/gku253
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Labbé R. M.,
    2. Holowatyj A.,
    3. Yang Z. Q.
    (2013). Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. Am. J. Transl. Res. 6, 1–15.
    OpenUrlPubMed
  33. ↵
    1. Lee M.,
    2. Daniels M. J.,
    3. Venkitaraman A. R.
    (2004). Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 23, 865–872. doi:10.1038/sj.onc.1207223
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Li W.,
    2. Zhao L.,
    3. Zang W.,
    4. Liu Z.,
    5. Chen L.,
    6. Liu T.,
    7. Xu D.,
    8. Jia J.
    (2011). Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem. Biophys. Res. Commun. 416, 372–378. doi:10.1016/j.bbrc.2011.11.045
    OpenUrlCrossRefPubMed
  35. ↵
    1. Li F.,
    2. Mao G.,
    3. Tong D.,
    4. Huang J.,
    5. Gu L.,
    6. Yang W.,
    7. Li G. M.
    (2013). The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell 153, 590–600. doi:10.1016/j.cell.2013.03.025
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Liu G.,
    2. Bollig-Fischer A.,
    3. Kreike B.,
    4. van de Vijver M. J.,
    5. Abrams J.,
    6. Ethier S. P.,
    7. Yang Z. Q.
    (2009). Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28, 4491–4500. doi:10.1038/onc.2009.297
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Loh Y. H.,
    2. Zhang W.,
    3. Chen X.,
    4. George J.,
    5. Ng H. H.
    (2007). Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes Dev. 21, 2545–2557. doi:10.1101/gad.1588207
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Lorbeck M. T.,
    2. Singh N.,
    3. Zervos A.,
    4. Dhatta M.,
    5. Lapchenko M.,
    6. Yang C.,
    7. Elefant F.
    (2010). The histone demethylase DmelA controls genes required for life span and male-specific sex determination in Drosophila. Gene 450, 8–17. doi:10.1016/j.gene.2009.09.007
    OpenUrlCrossRefPubMed
  39. ↵
    1. Luo W.,
    2. Chang R.,
    3. Zhong J.,
    4. Pandey A.,
    5. Semenza G. L.
    (2012). Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc. Natl. Acad. Sci. USA 109, E3367–E3376. doi:10.1073/pnas.1217394109
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Mallette F. A.,
    2. Richard S.
    (2012). JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Reports 2, 1233–1243. doi:10.1016/j.celrep.2012.09.033
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Mallette F. A.,
    2. Mattiroli F.,
    3. Cui G.,
    4. Young L. C.,
    5. Hendzel M. J.,
    6. Mer G.,
    7. Sixma T. K.,
    8. Richard S.
    (2012). RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J. 31, 1865–1878. doi:10.1038/emboj.2012.47
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Merok M. A.,
    2. Ahlquist T.,
    3. Røyrvik E. C.,
    4. Tufteland K. F.,
    5. Hektoen M.,
    6. Sjo O. H.,
    7. Mala T.,
    8. Svindland A.,
    9. Lothe R. A.,
    10. Nesbakken A.
    (2013). Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann. Oncol. 24, 1274–1282. doi:10.1093/annonc/mds614
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Northcott P. A.,
    2. Nakahara Y.,
    3. Wu X.,
    4. Feuk L.,
    5. Ellison D. W.,
    6. Croul S.,
    7. Mack S.,
    8. Kongkham P. N.,
    9. Peacock J.,
    10. Dubuc A.
    et al. (2009). Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat. Genet. 41, 465–472. doi:10.1038/ng.336
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Palomera-Sanchez Z.,
    2. Bucio-Mendez A.,
    3. Valadez-Graham V.,
    4. Reynaud E.,
    5. Zurita M.
    (2010). Drosophila p53 is required to increase the levels of the dKDM4B demethylase after UV induced DNA damage to demethylate histone H3-lysine 9. J. Biol. Chem. 285, 31370–31379. doi:10.1074/jbc.M110.128462
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Ponnaluri V. K.,
    2. Vavilala D. T.,
    3. Putty S.,
    4. Gutheil W. G.,
    5. Mukherji M.
    (2009). Identification of non-histone substrates for JMJD2A-C histone demethylases. Biochem. Biophys. Res. Commun. 390, 280–284. doi:10.1016/j.bbrc.2009.09.107
    OpenUrlCrossRefPubMed
  46. ↵
    1. Ribic C. M.,
    2. Sargent D. J.,
    3. Moore M. J.,
    4. Thibodeau S. N.,
    5. French A. J.,
    6. Goldberg R. M.,
    7. Hamilton S. R.,
    8. Laurent-Puig P.,
    9. Gryfe R.,
    10. Shepherd L. E.
    et al. (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247–257. doi:10.1056/NEJMoa022289
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Shi Y.,
    2. Whetstine J. R.
    (2007). Dynamic regulation of histone lysine methylation by demethylases. Mol. Cell 25, 1–14. doi:10.1016/j.molcel.2006.12.010
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Shi Y.,
    2. Lan F.,
    3. Matson C.,
    4. Mulligan P.,
    5. Whetstine J. R.,
    6. Cole P. A.,
    7. Casero R. A.,
    8. Shi Y.
    (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953. doi:10.1016/j.cell.2004.12.012
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Shi L.,
    2. Sun L.,
    3. Li Q.,
    4. Liang J.,
    5. Yu W.,
    6. Yi X.,
    7. Yang X.,
    8. Li Y.,
    9. Han X.,
    10. Zhang Y.
    et al. (2011). Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl. Acad. Sci. USA 108, 7541–7546. doi:10.1073/pnas.1017374108
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Shin S.,
    2. Janknecht R.
    (2007a). Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem. Biophys. Res. Commun. 359, 742–746. doi:10.1016/j.bbrc.2007.05.179
    OpenUrlCrossRefPubMed
  51. ↵
    1. Shin S.,
    2. Janknecht R.
    (2007b). Diversity within the JMJD2 histone demethylase family. Biochem. Biophys. Res. Commun. 353, 973–977. doi:10.1016/j.bbrc.2006.12.147
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Trojer P.,
    2. Zhang J.,
    3. Yonezawa M.,
    4. Schmidt A.,
    5. Zheng H.,
    6. Jenuwein T.,
    7. Reinberg D.
    (2009). Dynamic histone H1 isotype 4 methylation and demethylation by histone lysine methyltransferase G9a/KMT1C and the Jumonji domain-containing JMJD2/KDM4 proteins. J. Biol. Chem. 284, 8395–8405. doi:10.1074/jbc.M807818200
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Tsukada Y.,
    2. Fang J.,
    3. Erdjument-Bromage H.,
    4. Warren M. E.,
    5. Borchers C. H.,
    6. Tempst P.,
    7. Zhang Y.
    (2006). Histone demethylation by a family of JmjC domain-containing proteins. Nature 439, 811–816. doi:10.1038/nature04433
    OpenUrlCrossRefPubMedWeb of Science
  54. ↵
    1. Vilar E.,
    2. Tabernero J.
    (2013). Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov. 3, 502–511. doi:10.1158/2159-8290.CD-12-0471
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Vilar E.,
    2. Scaltriti M.,
    3. Balmaña J.,
    4. Saura C.,
    5. Guzman M.,
    6. Arribas J.,
    7. Baselga J.,
    8. Tabernero J.
    (2008). Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer 99, 1607–1612. doi:10.1038/sj.bjc.6604691
    OpenUrlCrossRefPubMed
  56. ↵
    1. Vinatzer U.,
    2. Gollinger M.,
    3. Müllauer L.,
    4. Raderer M.,
    5. Chott A.,
    6. Streubel B.
    (2008). Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin. Cancer Res. 14, 6426–6431. doi:10.1158/1078-0432.CCR-08-0702
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Whetstine J. R.,
    2. Nottke A.,
    3. Lan F.,
    4. Huarte M.,
    5. Smolikov S.,
    6. Chen Z.,
    7. Spooner E.,
    8. Li E.,
    9. Zhang G.,
    10. Colaiacovo M.
    et al. (2006). Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125, 467–481. doi:10.1016/j.cell.2006.03.028
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Wissmann M.,
    2. Yin N.,
    3. Müller J. M.,
    4. Greschik H.,
    5. Fodor B. D.,
    6. Jenuwein T.,
    7. Vogler C.,
    8. Schneider R.,
    9. Günther T.,
    10. Buettner R.
    et al. (2007). Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9, 347–353. doi:10.1038/ncb1546
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Yang Z. Q.,
    2. Imoto I.,
    3. Fukuda Y.,
    4. Pimkhaokham A.,
    5. Shimada Y.,
    6. Imamura M.,
    7. Sugano S.,
    8. Nakamura Y.,
    9. Inazawa J.
    (2000). Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 60, 4735–4739.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Yang L.,
    2. Lin C.,
    3. Liu W.,
    4. Zhang J.,
    5. Ohgi K. A.,
    6. Grinstein J. D.,
    7. Dorrestein P. C.,
    8. Rosenfeld M. G.
    (2011). ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 147, 773–788. doi:10.1016/j.cell.2011.08.054
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Young L. C.,
    2. McDonald D. W.,
    3. Hendzel M. J.
    (2013). Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation. J. Biol. Chem. 288, 21376–21388. doi:10.1074/jbc.M113.491514
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Zack T. I.,
    2. Schumacher S. E.,
    3. Carter S. L.,
    4. Cherniack A. D.,
    5. Saksena G.,
    6. Tabak B.,
    7. Lawrence M. S.,
    8. Zhang C. Z.,
    9. Wala J.,
    10. Mermel C. H.
    et al. (2013). Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140. doi:10.1038/ng.2760
    OpenUrlCrossRefPubMed
  63. ↵
    1. Zhang D.,
    2. Yoon H. G.,
    3. Wong J.
    (2005). JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2). Mol. Cell. Biol. 25, 6404–6414. doi:10.1128/MCB.25.15.6404-6414.2005
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

RSSRSS

Keywords

 Download PDF

Email
Research Article
Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway
Samah W. Awwad, Nabieh Ayoub
Biology Open 2015 4: 498-504; doi: 10.1242/bio.201410991
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article Navigation

Other journals from The Company of Biologists

Advertisement

Why publish with BiO?

Biology Open provides rapid publication for scientifically sound observations and valid conclusions in developmental, cell, experimental and translational biology. Submit your paper for an easy and fast publication process. Recent developmental biology highlights in in BiO include work by Teramoto et al., which looks at the change in epithelial characteristics in the anterior foregut in the absence of SOX2.

Hear from this month’s first authors: Setsuya Minami, Kate Quigley, Samantha Payne and Juan Garrido-Maraver talk about their papers and life as a researcher.

A study by Thomas Cansse and colleagues used bird-borne cameras on Australasian gannets in Bass Strait and found that animals foraging solitarily had lower levels of prey-capture success than animals foraging in groups. However, prey profitability was lower for group-foraging animals due to increased time expenditure to capture prey.